893440-43-2

Upstream product

• 501-53-1 benzyl chloroformate 
• 147269-67-8 (2-hydroxypyridin-3-yl)carbamic acid benzyl ester 
• 33630-99-8 2-hydroxy-3-aminopyridine 
• 74-88-4 methyl iodide 
• 147269-68-9 3-<<(benzyloxy)carbonyl>amino>-5-iodopyrid-2-one 

Downstream Products

• 893440-45-4 [2-methoxy-5-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)pyridin-3-yl]carbamic acid benzyl ester 
• 60719-84-8 amrinone 
• 934200-37-0 C₁₈H₁₅N₃O₃ 
• 893440-47-6 3-benzyloxycarbonylamino-5-[2-methylthio(4-pyrimidinyl)]-2-methoxypyridine 

Relevant academic research and scientific papers

ARYLPYRIDINONE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER

Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein Ar, R2, R4, R5, n and X are as defined in

Arylpyridinone ITK inhibitors for treating inflammation and cancer

Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein Ar, R2, R4, R5, n and X are as defined in

3, 5-DISUBSTITUTED PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES

The present invention relates to pyrid-2-one compounds of formula (I) useful as inhibitors of protein kinase of Tec family (e.g., Tec, Btk, Itk/Emt/Tsk, Bmx,Txk/Rlk) protein kinases. These compounds and pharmaceutically acceptable compositions thereof are

Synthesis of a stable pyridyl boronate and its reaction with aryl and heteroaryl halides

The synthesis and reaction of a versatile 5-pyridyl boronate is described. This intermediate can be used to synthesize a range of biologically interesting 2-(1H)-pyridones.

PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY PROTEIN KINASES FOR THE TREATMENT OF INFLAMMATORY, PROLIFERATIVE AND IMMUNOLOGICALLY-MEDIATED DISEASES

This invention describes compounds of Formula (I), or a pharmaceutically accepted salt thereof, wherein each R3 and R4 is independently H, halogen or C1-4aliphatic optionally substituted with halogen, C1-2aliphatic, OCH3, NO2, NH2, CN, NHCH3, SCH3, or N(CH)2. R2 is a 3-8membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R2 is optionally substituted with JR; each X1 and X2 is independently -C(O)-, -NR-, or -SO2- wherein one of X1 or X2 is -NR- and other of X1 or X2 is -C(O)- or -SO2-; R1 and R are as described herein; These compounds are effective as inhibitors of Tec family (e.g., Tec, Btk, Itk/Emt/Tsk, Bmx, Txk/Rlk) protein kinases. These compounds and pharmaceutically acceptable compositions thereof are useful for treating or preventing a variety of diseases, disorders or conditions, including, but not limited to, an autoimmune, inflammatory, proliferative, or hyperproliferative disease or an immunologically-mediated disease.